FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007220570> ?p ?o ?g. }

• W2007220570 endingPage "193" @default.
• W2007220570 startingPage "186" @default.
• W2007220570 abstract "Background: Platelet-rich plasma (PRP) is an autologous blood product used to treat acute and chronic tendon, ligament, and muscle injuries in over 86,000 athletes in the United States annually. The World Anti-Doping Agency (WADA) banned intramuscular PRP injections in competitive athletes in 2010 because of concerns that it may increase performance-enhancing growth factors. The ban on PRP was removed in 2011 because of limited evidence for a systemic ergogenic effect of PRP, but the growth factors within PRP remain prohibited. Purpose: To quantify the effect of PRP injection on systemic growth factors with performance-enhancing effects and to identify molecular markers to detect treated athletes. Study Design: Descriptive laboratory study. Methods: Six ergogenic growth factors monitored by WADA—human growth hormone (hGH), insulin-like growth factor–1 (IGF-1), insulin-like growth factor binding protein–3 (IGFBP-3), basic fibroblast growth factor (bFGF or FGF-2), vascular endothelial growth factor (VEGF), and platelet-derived growth factor–BB (PDGF-BB)—were measured in 25 patients before (baseline) and at 0.25, 3, 24, 48, 72, and 96 hours after intratendinous leukocyte-rich PRP injection. Eating and exercise were prohibited for 3 hours before testing. Growth factors were quantified by enzyme-linked immunosorbent assay, and the change relative to each patient’s baseline was calculated. Results: Relative to serum, PRP contained significantly more bFGF (226 vs 5 pg/mL), VEGF (1426 vs 236 pg/mL), and PDGF-BB (26,285 vs 392 pg/mL), but IGF-1 and hGH were not elevated. Serum levels increased significantly for IGF-1 at 24 and 48 hours, for bFGF at 72 and 96 hours, and for VEGF at 3, 24, 48, 72, and 96 hours after PRP injection. Additionally, VEGF was increased in all 25 patients after PRP treatment. Conclusion: Serum IGF-1, VEGF, and bFGF levels are significantly elevated after PRP injection, supporting a possible ergogenic effect of PRP. An indirect marker for hGH doping, the product of IGFBP-3 × IGF-1, also significantly increased after PRP. Platelet-rich plasma appears to trigger an increase in circulating growth factors through activating biological pathways rather than by serving as a vehicle for the direct delivery of presynthesized growth factors. Elevated VEGF was observed in all patients after PRP, and ≥88% of patients had elevated VEGF at each time point from 3 to 96 hours after PRP, suggesting that VEGF may be a sensitive molecular marker to detect athletes recently treated with PRP. Clinical Relevance: This is the first and only adequately powered study of the systemic effects of PRP. We present evidence that PRP contains and may trigger systemic increases in substances currently banned in competitive athletes. Finally, we provide evidence that VEGF could serve as a useful molecular marker to detect athletes treated with PRP." @default.
• W2007220570 created "2016-06-24" @default.
• W2007220570 creator A5015524353 @default.
• W2007220570 creator A5043937615 @default.
• W2007220570 creator A5045816949 @default.
• W2007220570 creator A5063114595 @default.
• W2007220570 creator A5080109321 @default.
• W2007220570 date "2012-12-04" @default.
• W2007220570 modified "2023-10-01" @default.
• W2007220570 title "The Systemic Effects of Platelet-Rich Plasma Injection" @default.
• W2007220570 cites W1966530677 @default.
• W2007220570 cites W1967299240 @default.
• W2007220570 cites W1968742746 @default.
• W2007220570 cites W1980530794 @default.
• W2007220570 cites W1980992626 @default.
• W2007220570 cites W1983763042 @default.
• W2007220570 cites W2013509105 @default.
• W2007220570 cites W2019424555 @default.
• W2007220570 cites W2028339551 @default.
• W2007220570 cites W2042394833 @default.
• W2007220570 cites W2042488522 @default.
• W2007220570 cites W2046563190 @default.
• W2007220570 cites W2050087880 @default.
• W2007220570 cites W2081075932 @default.
• W2007220570 cites W2088986145 @default.
• W2007220570 cites W2096813909 @default.
• W2007220570 cites W2102303758 @default.
• W2007220570 cites W2102335423 @default.
• W2007220570 cites W2105421207 @default.
• W2007220570 cites W2112102525 @default.
• W2007220570 cites W2114397019 @default.
• W2007220570 cites W2114716357 @default.
• W2007220570 cites W2129838994 @default.
• W2007220570 cites W2136871488 @default.
• W2007220570 cites W2148080767 @default.
• W2007220570 cites W2164505387 @default.
• W2007220570 cites W2318133426 @default.
• W2007220570 doi "https://doi.org/10.1177/0363546512466383" @default.
• W2007220570 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23211708" @default.
• W2007220570 hasPublicationYear "2012" @default.
• W2007220570 type Work @default.
• W2007220570 sameAs 2007220570 @default.
• W2007220570 citedByCount "118" @default.
• W2007220570 countsByYear W20072205702013 @default.
• W2007220570 countsByYear W20072205702014 @default.
• W2007220570 countsByYear W20072205702015 @default.
• W2007220570 countsByYear W20072205702016 @default.
• W2007220570 countsByYear W20072205702017 @default.
• W2007220570 countsByYear W20072205702018 @default.
• W2007220570 countsByYear W20072205702019 @default.
• W2007220570 countsByYear W20072205702020 @default.
• W2007220570 countsByYear W20072205702021 @default.
• W2007220570 countsByYear W20072205702022 @default.
• W2007220570 countsByYear W20072205702023 @default.
• W2007220570 crossrefType "journal-article" @default.
• W2007220570 hasAuthorship W2007220570A5015524353 @default.
• W2007220570 hasAuthorship W2007220570A5043937615 @default.
• W2007220570 hasAuthorship W2007220570A5045816949 @default.
• W2007220570 hasAuthorship W2007220570A5063114595 @default.
• W2007220570 hasAuthorship W2007220570A5080109321 @default.
• W2007220570 hasConcept C126322002 @default.
• W2007220570 hasConcept C134018914 @default.
• W2007220570 hasConcept C167734588 @default.
• W2007220570 hasConcept C170493617 @default.
• W2007220570 hasConcept C180361614 @default.
• W2007220570 hasConcept C1862650 @default.
• W2007220570 hasConcept C2775960820 @default.
• W2007220570 hasConcept C2777025900 @default.
• W2007220570 hasConcept C2780076745 @default.
• W2007220570 hasConcept C2780689927 @default.
• W2007220570 hasConcept C2781054738 @default.
• W2007220570 hasConcept C2781294074 @default.
• W2007220570 hasConcept C71924100 @default.
• W2007220570 hasConcept C89560881 @default.
• W2007220570 hasConceptScore W2007220570C126322002 @default.
• W2007220570 hasConceptScore W2007220570C134018914 @default.
• W2007220570 hasConceptScore W2007220570C167734588 @default.
• W2007220570 hasConceptScore W2007220570C170493617 @default.
• W2007220570 hasConceptScore W2007220570C180361614 @default.
• W2007220570 hasConceptScore W2007220570C1862650 @default.
• W2007220570 hasConceptScore W2007220570C2775960820 @default.
• W2007220570 hasConceptScore W2007220570C2777025900 @default.
• W2007220570 hasConceptScore W2007220570C2780076745 @default.
• W2007220570 hasConceptScore W2007220570C2780689927 @default.
• W2007220570 hasConceptScore W2007220570C2781054738 @default.
• W2007220570 hasConceptScore W2007220570C2781294074 @default.
• W2007220570 hasConceptScore W2007220570C71924100 @default.
• W2007220570 hasConceptScore W2007220570C89560881 @default.
• W2007220570 hasIssue "1" @default.
• W2007220570 hasLocation W20072205701 @default.
• W2007220570 hasLocation W20072205702 @default.
• W2007220570 hasOpenAccess W2007220570 @default.
• W2007220570 hasPrimaryLocation W20072205701 @default.
• W2007220570 hasRelatedWork W1978292533 @default.
• W2007220570 hasRelatedWork W1982422595 @default.
• W2007220570 hasRelatedWork W2027661239 @default.
• W2007220570 hasRelatedWork W2056741426 @default.
• W2007220570 hasRelatedWork W2064563396 @default.

• next